🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
To maximise the accessibility and benefit of PARP inhibitors to eligible pa...
Status
Completed
Location
Research Site
Start Date
2021-05-02
Trial ID
NCT04991051
This observational retrospective-prospective study aims to evaluate the pre...
Status
Active Not Recruiting
Location
Dept. Medical Oncology
Start Date
2025-12-01
Trial ID
NCT07303218
Treatments Being Tested
In tumors with a defect in the homologous recombination (HR) pathway, doubl...
Status
Withdrawn
Location
Multiple Locations
Start Date
2019-11
Trial ID
NCT03044795
Treatments Being Tested
This randomized phase II trial studies how well olaparib with or without at...
Status
Active Not Recruiting
Location
Mayo Clinic Hospital in Arizona
Start Date
2017-03-30
Trial ID
NCT02849496
This is a multicenter, prospective, randomized, open-label phase II study e...
Status
Completed
Location
Kliniken Esslingen, Gynäkologie Onkologie
Start Date
2016-09
Trial ID
NCT02789332
Treatments Being Tested
This phase III trial compares the effect of olaparib for one year versus tw...
Status
Recruiting
Location
University of Alabama at Birmingham Cancer Center
Start Date
2025-03-12
Trial ID
NCT06580314
Treatments Being Tested
PARP inhibitors are most effective in homologous recombinant (HR) deficient...
Status
Terminated
Location
University Medical Center Groningen
Start Date
2019-01-21
Trial ID
NCT04780945
Treatments Being Tested
The homologous recombination deficiency (HRD) status in Chinese population ...
Status
Unknown
Location
Lei Li
Start Date
2019-12-07
Trial ID
NCT04190667
Treatments Being Tested
The association between homologous recombination (HR) gene mutations and ho...
Status
Unknown
Location
Lei Li
Start Date
2022-03-26
Trial ID
NCT05310370
Treatments Being Tested